Default



Default

Home | Contact Us | Site Index | Search UW:

Peter C. Wu, M.D.

 

Patient Services:

Veterans Affairs Medical Center

Academic Office:

Phone: (206) 764-2141

E-mail:
pcwu@u.washington.edu

Fax: (206) 764-2529

Address:
Peter C. Wu, M.D.
Veterans Affairs Puget Sound Health Care System
Dept. of Surgery (112)
1660 S. Columbian Way
Seattle, WA 98108

Assistant Professor

Faculty Appointment:

University of Washington, Assistant Professor, 2004 - present.

Education:

Fellowships: Surgical Oncology, University of Chicago, 2001 - 04.
Surgical Oncology, NIH, National Cancer Institute, Surgery Branch, 1995 - 98.

Residency: University of Connecticut, 1993 - 2001.

M.D. Degree: Jefferson Medical College, 1993.

Board Certified: General Surgery, 2003.

Clinical Interests:

Surgical oncology: multidisciplinary care, hepatobiliary and pancreatic cancer, gastrointestinal cancer, inflammatory bowel disease, soft tissue sarcoma, melanoma, endocrine neoplasms, sentinel node and minimally invasive surgery.

Research Interests:

Cytokine gene therapy, tumor angiogenesis, molecular profiling, GI tumor banking, clinical trials, surgical outcomes, telemedicine outreach program.

Selected Publications:

Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger A, Turner E, Wilson O, Libutti SK.  In vivo sensitivity of human tumors to tumor necrosis factor (TNF)-a is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAP II).  Cancer Res, 59(1):205-12, 1999.

Lans TE, ten Hagen TL, van Horssen R, Wu PC, van Tiel ST, Libutti SK, Alexander HR, Eggermont AM.  Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.  Ann Surg Oncol, 9(8):812-9, 2002.

Wu PC, Posner MC.  The role of surgery in the management of oesophageal cancer. Lancet Oncology, 4: 481-88, 2003.

Wu PC, Langerman A, Ryan CW, Hart J, Swiger S, Posner MC. Surgical management of gastrointestinal stromal tumors in the imatinib (STI-571) era.  Surgery,  134:656-66, 2003.

Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodrigues M, Bartlett DL, Libutti SK, Pingpank JF, Alexander HR.  Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion.  J Gastrointest Surg, 8:200-7, 2004.

 

reviewed 08/04